Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Quelling Qualms about Revlimid

Revlimid's survival data trumps secondary cancer risk in maintenance setting

Updated Phase III data on the use of Celgene Corp.'s Revlimid lenalidomide as maintenance therapy in multiple myeloma have quelled fears that the risk of second primary malignancies might outweigh the drug's survival benefit.

Questions about a possible association between Revlimid and second primary malignancies (SPMs) first cropped up at the American Society of Hematology meeting in December. The observations came from three ongoing Phase III trials in which higher rates of SPMs were

Read the full 735 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers